BIOMAT Database Logo BIOMAT Database Logo

Antipyrine clearance and response to interferon therapy in chronic hepatitis. 1997

A Fabbri, and G P Bianchi, and G Marchesini

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D006505 Hepatitis INFLAMMATION of the LIVER. Hepatitides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

A Fabbri, and G P Bianchi, and G Marchesini
Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C.
October 1995, Hepatology (Baltimore, Md.),
A Fabbri, and G P Bianchi, and G Marchesini
Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
April 1994, British journal of clinical pharmacology,
A Fabbri, and G P Bianchi, and G Marchesini
Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C.
January 1995, Journal of hepatology,
A Fabbri, and G P Bianchi, and G Marchesini
Hepatitis B vaccine and antipyrine clearance.
January 1985, Journal of medicine,
A Fabbri, and G P Bianchi, and G Marchesini
Hepatitis C virus genotypes in chronic hepatitis and response to interferon-alpha therapy.
November 1993, The Journal of infectious diseases,
A Fabbri, and G P Bianchi, and G Marchesini
Response to interferon therapy in children with chronic hepatitis C.
October 1995, The Journal of pediatrics,
A Fabbri, and G P Bianchi, and G Marchesini
Caffeine clearance in patients with chronic viral hepatitis: before and after interferon therapy.
June 2001, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
A Fabbri, and G P Bianchi, and G Marchesini
Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy.
April 1997, Journal of hepatology,
A Fabbri, and G P Bianchi, and G Marchesini
Predictive factors in the response to interferon therapy in chronic hepatitis C.
April 1995, Liver,
A Fabbri, and G P Bianchi, and G Marchesini
Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.
May 2001, Journal of viral hepatitis,
Copied contents to your clipboard!